Theravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of ($0.17), $0.04 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $15.69 million versus the consensus estimate of $15.4 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.